Edgar Filing: PROGENICS PHARMACEUTICALS INC - Form 4

Form 4	CS PHARMACEU	TICALS	INC							
February 09 FORN Check t if no lor subject Section Form 4 Form 5 obligation may con See Inst 1(b).	A 4 his box nger to 16. or STATEM Filed pur Section 17(4)	IENT OF suant to S a) of the F	Wa F CHAN Section 1 Public U	shington, NGES IN SECUR (6(a) of th tility Hole	, D.C. 205 BENEFI RITIES ne Securitio	6 49 C IAI es Ex pany	COWN	OMMISSION ERSHIP OF Act of 1934, 1935 or Section	OMB Number: Expires: Estimated a burden hou response	rs per
(Print or Type	Responses)									
	Address of Reporting lealthcare Master I		Symbol PROGI	ENICS MACEUT	I Ticker or T	-	>	5. Relationship of 1 ssuer (Check Director	Reporting Pers all applicable X 109)
(Last) (First) (Middle) 20 GENESIS CLOSE, ANSBACHER HOUSE, SECOND FLOOR, 1344			3. Date of Earliest Transaction(Month/Day/Year)02/07/2017					Officer (give t	itleOtho	er (specify
GRAND C	(Street)	1-1108		endment, Da nth/Day/Year	ate Original r)		-	5. Individual or Joi Applicable Line) Form filed by Or X Form filed by M	ne Reporting Per	rson
(City)		(Zip)	Tab	le I - Non-I	Derivative S	ecurit		Person	or Beneficial	ly Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deem Execution any (Month/Da	ed Date, if	3. 4. Securities Acquired (A) Transactionor Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8) (A) or Code V Amount (D) Price			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock	02/07/2017			S	100,000	D		7,851,169	D (1)	
Common Stock	02/07/2017			S	50,000	D	\$ 9.65	7,801,169	D (1)	
Common Stock	02/09/2017			S	100,000	D	\$ 9.75	7,701,169	D (1)	
Common Stock	02/09/2017			S	100,000	D	\$ 9.66	7,601,169	D (1)	

Edgar Filing: PROGENICS PHARMACEUTICALS INC - Form 4

Common	02/09/2017	c	1,300	D	³ 7 500 860	$\mathbf{D}(1)$
Stock	02/09/2017	3	1,500	D	9.685 ^{7,599,869}	$D \underline{(\cdot)}$

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02) required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. onNumber of Derivative Securities		ate	7. Titl Amou Under Secur (Instr.	ınt of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owne
	Security				Acquired (A) or						Follo Repo
					Disposed						Trans
					of (D)						(Instr
					(Instr. 3,						
					4, and 5)						
									Amount		
						Date Exercisable	Expiration Date	Title	or Number of		
				Code V	(A) (D)				Shares		

Reporting Owners

Reporting Owner Name / Address		Relationsh		
	Director	10% Owner	Officer	Other
Broadfin Healthcare Master Fund Ltd 20 GENESIS CLOSE ANSBACHER HOUSE, SECOND FLOOR, 1344 GRAND CAYMAN, E9 KY1-1108		Х		
KOTLER KEVIN C/O BROADFIN CAPITAL, LLC 300 PARK AVENUE, 25TH FLOOR NEW YORK, NY 10022		Х		
Broadfin Capital, LLC 300 PARK AVENUE, 25TH FLOOR NEW YORK, NY 10022		Х		
Signatures				
BROADFIN HEALTHCARE MASTER FUND, L' Director	02/09/2017			
**Signature of Reporting Persor	Date			

Edgar Filing: PROGENICS PHARMACEUTICALS INC - Form 4

/s/ Kevin Kotler	02/09/2017				
**Signature of Reporting Person	Date				
BROADFIN CAPITAL, LLC By: /s/ Kevin Kotler, Managing Member	02/09/2017				
**Signature of Reporting Person	Date				
Explanation of Responses:					

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The Common Stock are held in the account of Broadfin Healthcare Master Fund, Ltd., a private investment fund managed by Broadfin Capital, LLC and may be deemed to be beneficially owned by Kevin Kotler, managing member of Broadfin Capital, LLC. Each of

(1) Broadfin Capital, LLC, Broadfin Healthcare Master Fund, Ltd. and Kevin Kotler disclaim beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein, and affirmatively disclaim being a "group" for purposes of Section 16 of the Securities Exchange Act of 1934, as amended.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.